4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations

Abstract : (5aR)-5a-C-pentyl-4-epi-isofagomine 1 is a powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B. We report herein an improved synthesis of this compound and analogs (5a-C-methyl, pentyl, nonyl and phenylethyl derivatives), and a crystal structure of a synthetic intermediate that confirms its configuration resulting from the addition of a Grignard reagent. These compounds were evaluated as glycosidase inhibitors and their potential as chaperones for mutant lysosomal galactosidases determined. Based on these results and on docking studies, the 5-C-pentyl derivative 1 was selected as the optimal structure for further investigations: this compound induces the maturation of mutated β-galactosidase in fibroblasts of a GM1-gangliosidosis patient and promote the decrease of keratan sulfate and oligosaccharide load in patient cells. Compound 1 is clearly capable of restoring β-galactosidase activity and of promoting maturation of the protein, which should result in significant clinical benefit. These properties strongly support the development of compound 1 for the treatment of GM1-gangliosidosis and Morquio disease type B patients harboring β-galactosidase mutations sensitive to pharmacological chaperoning.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-orleans.archives-ouvertes.fr/hal-02179720
Contributor : Pascale Solon <>
Submitted on : Thursday, July 11, 2019 - 10:28:03 AM
Last modification on : Friday, July 12, 2019 - 1:12:23 AM

Identifiers

Collections

Citation

Sophie Front, Sofia Almeida, Vincent Zoete, Julie Charollais-Thoenig, Estelle Gallienne, et al.. 4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations. Bioorganic and Medicinal Chemistry, Elsevier, 2018, 26 (20), pp.5462-5469. ⟨10.1016/j.bmc.2018.09.023⟩. ⟨hal-02179720⟩

Share

Metrics

Record views

15